WallStSmart
CBUS

Cibus Global LLC

NASDAQ: CBUS · HEALTHCARE · BIOTECHNOLOGY

$1.40
+9.37% today

Updated 2026-04-30

Market cap
$114.42M
P/E ratio
P/S ratio
31.44x
EPS (TTM)
$-2.78
Dividend yield
52W range
$1 – $4
Volume
0.7M

Cibus Global LLC (CBUS) Stock Valuation Analysis

Fair value estimate, historical valuation range, and quality signals for CBUS.

WallStSmart Verdict
Overvalued

Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.

Smart Value Score: 14 / 100
P/E (TTM)
Not meaningful for this profile
PEG
Margin of Safety
+87.54%
Fair value $16.78 vs $1.40
EV / EBITDA
0.0x

CBUS historical valuation range

Where current P/E sits in CBUS's own 5Y range.

Insufficient historical data for 5Y percentile analysis

CBUS intrinsic value (DCF)

DCF-based fair value estimate vs current market price.

Current price
$1.40
Market value
Intrinsic value
$16.78
DCF estimate
Margin of safety
+87.54%
+1098.6% upside to fair value

Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.

CBUS valuation signals

Quick-read green flags, caution flags, and risks based on current metrics.

Strong margin of safety
Current price 87.5% below DCF intrinsic value estimate. Meaningful downside cushion.

P/E Ratio — History

No historical P/E data available

P/S Ratio — History

Current: 31.44x

Is CBUS overvalued in 2026?

Cibus Global LLC (CBUS) currently trades at $1.40 per share with a market capitalization of $114,425,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 14/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.

CBUS currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 31.4x, the market is valuing the company primarily on its revenue rather than its earnings.

Our discounted cash flow model estimates CBUS's intrinsic value at $16.78 per share, against the current market price of $1.40. This implies a margin of safety of +87.54%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.

The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.

Bottom line: CBUS appears richly valued on our framework, with a Smart Value Score of 14/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.

Frequently asked questions

Is CBUS overvalued in 2026?

Based on a Smart Value Score of 14/100, CBUS appears overvalued. Current price exceeds what fundamentals currently justify.

What is CBUS's fair value?

Our DCF model estimates CBUS's intrinsic value at $16.78 per share, versus the current price of $1.40. This produces a margin of safety of +87.54%.

What P/E ratio does CBUS trade at?

CBUS does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.

Is CBUS a buy based on valuation?

WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 14/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.

How does CBUS's valuation compare to its history?

Insufficient historical valuation data exists yet for a confident percentile read on CBUS.

What is CBUS's Smart Value Score?

CBUS's Smart Value Score is 14/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.